跳到主要內容

臺灣博碩士論文加值系統

(35.175.191.36) 您好!臺灣時間:2021/08/01 00:16
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:蕭宇涵
研究生(外文):Yu-Han Hsiao
論文名稱:乳酸菌抑制幽門螺旋桿菌之篩選與功效評估--體外試驗及初步人體試驗
論文名稱(外文):Screening and Efficacy Assessment of Lactic Acid Bacteria for the Inhibition of Helicobacter pylori: in vitro experiments and a preliminary human trial
指導教授:黃青真黃青真引用關係王雪芳王雪芳引用關係
指導教授(外文):Ching-jang HuangHsueh-Fang Wang
學位類別:碩士
校院名稱:弘光科技大學
系所名稱:營養醫學研究所
學門:醫藥衛生學門
學類:營養學類
論文種類:學術論文
論文出版年:2012
畢業學年度:100
語文別:中文
論文頁數:118
中文關鍵詞:乳酸菌幽門螺旋桿菌13C尿素呼氣試驗胃癌細胞PROBIO-G
外文關鍵詞:lactic acid bacteriaHelicobacter pylori13C urea breath testgastric cancerPROBIO-G
相關次數:
  • 被引用被引用:0
  • 點閱點閱:590
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
中文摘要
幽門螺桿菌 (Helicobacter pylori, H. pylori) 是胃潰瘍、十二指腸疾病及胃癌的致病因子之ㄧ。現階段臨床治療仍是以抗生素為主,但因會產生副作用及造成抗生素耐藥性,影響病人持續服藥的意願,降低治癒率。因此,本研究擬暸解乳酸菌抑制幽門螺旋桿菌的作用,將其篩選出之乳酸菌株進行初步人體試驗,評估乳酸菌在體內抑制幽門螺旋桿菌之功效。本研究分兩階段進行,第一階段先以孔洞擴散法及試管內抑菌作用,篩選出具抑制幽門螺旋桿菌生長之乳酸菌,再以胃癌細胞株AGS及TSGH 9201進行細胞吸附試驗,確認篩選出同時具抑菌及吸附效果趨勢之乳酸菌株後,製成人體試驗樣品以供新產製新乳酸菌產品。第二階段以第一階段開發之乳酸菌產品進行人體試驗,利用13C尿素呼氣試驗及糞便抗原檢測於2011年9-10月篩選150名自願者,將具陽性反應之受試者19人,以隨機雙盲模式分成乳酸菌組與安慰劑組,另以陰性反應者作為對照組,以評估乳酸菌抑制幽門螺旋桿菌之功效,並測試其抑制幽門螺旋桿菌的功效及對人體試驗之安全性評估。結果顯示,所篩選出的3株乳酸菌在2株幽門螺旋桿菌中ATCC 700392及在BCRC 15415具有較佳抑制效果,對胃癌細胞株中等具有些微吸附效果,因此,新開發乳酸菌產品益生衛(PROBIO-G)於人體試驗,以SPSS 統計軟體之paired t-test分析其結果發現其具有抑制幽門螺旋桿菌之趨勢,且無發現明顯副作用。綜合以上結果顯示,本研究所篩選出具有抑制幽門螺旋桿菌之效果的乳酸菌3株,理論上應具有發展為抑制幽門螺旋桿菌之保健食品的潛力。雖於人體試驗中PROBIO-G未對幽門螺旋桿菌具顯著性抑制成效,但若能增加研究樣本數可能可顯示抑制效果。

關鍵詞:乳酸菌、幽門螺旋桿菌、13C尿素呼氣試驗、胃癌細胞、PROBIO-G

Abstract
Helicobacter pylori(H. pylori) is a gastric ulcer, duodenal disease or pathogenic agent of gastric cancer in Taiwan. Still at this stage of clinical treatment is antibiotics, but will have adverse side effects and cause of antibiotic resistance, affect patients' ongoing medication will reduce the cure rate. Therefore, this study intends to understand the lactic acid bacteria inhibit the role of Helicobacter pylori, screening of lactic acid bacteria strains for initial human trials to assess the inhibition of Helicobacter pylori effect of lactic acid bacteria in the body. In this study, conducted in two phases, the first phase, the well diffusion method and in vitro antibacterial screening by the inhibition of H. pylori growth of lactic acid bacteria, gastric cancer cell line AGS and TSGH 9201 cell assay to confirm the screening of antibacterial and trends of the adsorption effect of lactic acid bacteria strains, made of human test samples for the new production of lactic acid bacteria products. The second phase of human trials with the first phase of development of lactic acid bacteria products, using the 13C urea breath test and stool antigen test screening in September-October 2011, 150 volunteers, will be divided into lactic acid bacteria group and the placebo group in subjects with positive reactions, 19 were randomized, double-blind, mode as the control group, and the other negative, assessment of lactic acid bacteria inhibit the effect of H. pylori, and to test the efficacy of inhibition of Helicobacter pylori and assessment of the safety of human trials. The results showed , Filtered out of three lactic acid bacteria in the two H. pylori ATCC 700392 and BCRC 15415 has a better inhibitory effect, Slight adsorption effect on gastric cancer cell strains, Therefore, the newly developed product of lactic acid bacteria prebiotics Wei (PROBIO-G) in human trials, SPSS statistical software, paired t-test analysis of the results found to inhibit the trend of Helicobacter pylori, and no obvious side effects.These results indicate that, in this study screened to inhibit the effects of lactic acid bacteria of the Helicobacter pylori 3, in theory, should have the potential inhibition of H. pylori health food. Although in PROBIO-G in human trials of Helicobacter pylori with significant inhibition effects, but it would increase the study sample size may be the inhibitory effect.

Key words: lactic acid bacteria, Helicobacter pylori, 13C urea breath test, gastric cancer, PROBIO-G

目 錄
頁次
中文摘要………………………………………………………III
英文摘要………………………………………………………V
縮寫表……………………………………………………………XVII
第一章 緒論…………………………………………………… 1
第二章 文獻回顧…………………………………………… 3
一、幽門螺旋桿菌…………………………………………… 3
(一) 幽門螺旋桿菌之發現…………………………… 3
(二) 幽門螺旋桿菌之特性…………………………… 4
(三) 幽門螺旋桿菌與疾病之關係……………… 4
(四) 幽門螺旋桿菌及其致病因子……………… 5
(五) 幽門螺旋桿菌診斷與治療…………………… 7
二、乳酸菌………………………………………………………… 10
(一) 乳酸菌之定義及特性…………………………… 10
(二) 乳酸菌之分類………………………………………… 10
(三) 乳酸菌在人體內之保健功效……………… 11
1、抑制致病菌維持腸道內菌叢之平衡……… 11
2、緩和乳糖不耐症………………………………………… 12
3、增加營養價值……………………………………………… 12
4、降低血清中膽固醇……………………………………… 13
5、抗癌性…………………………………………………………… 14
6、降血壓功能…………………………………………………… 15
7、增強免疫作用……………………………………………… 16
8、預防骨質疏鬆……………………………………………… 16
三、乳酸菌抑制幽門螺旋桿菌之相關研究…… 17
第三章 材料與方法…………………………………………… 21
一、乳酸菌株之篩選………………………………………… 21
(一)實驗材料……………………………………………………… 21
1、實驗菌株………………………………………………………… 21
2、實驗細胞株…………………………………………………… 21
3、培養基及藥品……………………………………………… 22
二、藥品與培養基配製…………………………………… 22
1、菌種培養基配製………………………………………… 22
三、實驗方法與步驟……………………………………… 23
(一) 乳酸菌保存與活化……………………………… 23
(二)幽門螺旋桿菌保存與活化……………………… 23
(三) 乳酸菌抑制幽門螺旋桿菌試驗--孔洞擴散法… 24
(四) 試管內乳酸菌抑制幽門螺旋桿菌……… 24
(五) 細胞吸附試驗………………………………………… 25
(六) API 50 CHL 乳酸菌菌種鑑定……… 26
四、人體實驗…………………………………………………… 28
(一)試驗設計與架構……………………………………… 28
(二)研究倫理…………………………………………………… 28
(三)研究對象…………………………………………………… 29
(四)研究方法…………………………………………………… 31
1、受試物成分………………………………………………… 31
2、資料收集……………………………………………………… 32
(1) 個人基本資料……………………………………………32
(2) 24 小時飲食回憶記錄……………………………34
(3) 腸胃道症狀紀錄…………………………………………34
(4) 血液常規分析……………………………………………34
(5) 血液生化分析……………………………………………35
(6) 13C 尿素呼氣試驗…………………………………35
(7) 糞便抗原檢測……………………………………………35
五、統計分析…………………………………………………… 37
第四章 結果與討論………………………………………… 37
一、乳酸菌株之篩選………………………………………… 37
(一) 乳酸菌抑制幽門螺旋桿菌--孔洞擴散法……… 37
(二) 試管內乳酸菌抑制幽門螺旋桿菌………… 38
(三) 細胞吸附試驗…………………………………………… 42
(四) API 50 CHL 乳酸菌菌種鑑定………… 44
二、人體試驗……………………………………………………… 44
(一) 人體測量…………………………………………………… 44
1、實驗對象………………………………………………………… 44
2、體重、腰圍及體脂肪率分析……………………… 44
3、脈膊與血壓分析…………………………………………… 47
(二) 血液生化值………………………………………………… 49
1、血糖分析………………………………………………………… 49
2、血球特性分析………………………………………………… 50
3、血脂分析………………………………………………………… 51
4、甲狀腺功能分析…………………………………………… 52
5、肝功能分析…………………………………………………… 53
6、腎功能分析…………………………………………………… 54
7、血中電解質分析…………………………………………… 55
8、蛋白質營養分析…………………………………………… 57
(三) 13C 尿素呼氣試驗……………………………… 57
(四) 糞便抗原檢測………………………………………… 60
(五) 24 小時飲食回憶紀錄………………………… 61
(六) 腸胃道狀況紀錄……………………………………… 63
第五章 研究限制………………………………………………… 65
第六章 結論………………………………………………………… 66
第七章 圖表結果………………………………………………… 67
第八章 參考文獻………………………………………………… 99
第九章 附錄………………………………………………………… 111
第八章 參考文獻
中華民國營養師公會全國聯合會。簡易營養量計算表分析飲食內容之營養素成分。http://www.dietitians.org.tw/download_frame.php。

白慧瑩。以人體試驗評估海藻複方調節體重與體脂之功能。國立台灣海洋大學食品科學系碩士論文。2008。

行政院衛生署。公告之「健康食品之腸胃功能改善評估方法」。http://www.doh.gov.tw/CHT2006/DM/SEARCH_RESULT.aspx。2003。

吳幸娟、吳佳娟、金惠民、胡淑惠、陳惠欣、章樂綺、張琳、黃惠煐、曾美智、劉慧蓉、蔡秀玲。營養評估。華格那。2007。

林天送。醫學的發現—胃炎、胃潰瘍、胃癌與幽門螺旋桿菌。科學發展459期66-69頁。2011。

林佩佩。嬰兒糞便來源之乳酸菌抑制腸毒性及腸凝集性大腸桿菌生長能力之抑菌活性體外試驗。靜宜大學食品營養研究所碩士論文。2006。

翁麗秋,陳啟清,郭佑啟,陳佩伶,黃媛芝,林明瀅。幽門螺旋桿菌簡介。感染控制雜誌15卷3期167-171頁。2005。

彭振雄。Helicobacter pylori感染小白鼠動物模式建立的探討。國立中興大學獸醫學系碩士論文。1997。

曾屏輝。幽門螺旋桿菌會傳染嗎?。台大醫網54期23-25頁。2010。

黃美瑩。乳酸菌之保健功效。水試專訊14期。2006。

黃莉芳。具抑制幽門桿菌之乳酸菌的篩選及應用。國立中興大學食品科學系碩士論文。2002。

蔡承諺,林英欽,周碩渠。幽門螺旋桿菌之感染與治療。家庭醫學與基層醫療26卷3期92-98頁。2011。

賴淑娥。評估乳酸菌保健食品不易形成體脂肪之功效。弘光科技大學食品暨應用生物科技所碩士論文。2011。

魏明敏、卞秀娟、王瑞蓮、蔡秀玲、楊淑惠。實用公共衛生營養學。華格那。2007。
譚健民。幽門螺旋桿菌導致胃黏膜傷害的免疫致病機轉~由細菌毒力因子(Virulence Factor)談起。台灣醫界 51卷1期12-16頁。2008。

Ahmed N. 23 years of the discovery of Helicobacter pylori: is the debate over? Ann Clin Microbiol Antimicrob. 2005 Oct;4:17.

Aiba Y, Suzuki N, Kabir AM, Takagi A, Koga Y. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic model. Am J Gastroenterol. 1998 Nov;93(11):2097-101.

Aktepe OC, Çiftçi İH, Şafak B, Uslan İ, Dilek FH. Five methods for detection of Helicobacter pylori in the Turkish population. World J Gastroenterol. 2011 Dec;17(47):5172-6.

An H M, Park S Y, Lee D K, Kim J R, Cha M K , Lee S W, Lim H T, Kim K J and Ha N J. Antiobesity and lipid-lowering effects of Bifidobacterium spp. in high fat diet-induced obese rats. Lipids Health Dis. 2011 Jul;10:116.

Andersson U, Bränning C, Ahrné S, Molin G, Alenfall J, Onning G, Nyman M, Holm C. Probiotics lower plasma glucose in the high-fat fed C57BL/6J mouse. Benef Microbes. 2010 Jun;1(2):189-96.

Armuzzi A, Cremonini F, Bartolozzi F, Canducci F, Candelli M, Ojetti V, Cammarota G, Anti M, De Lorenzo A, Pola P, Gasbarrini G,Gasbarrini A. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2001 Feb;15(2):163-9.

Banerjee S, Hawksby C, Miller S, Dahill S, Beattie AD, McColl K E L. Effect of Helicobacter pylori and its eradication on gastric uice ascorbic acid. Gut. 1994 Mar;35(3):317-22.

Bhatia SJ, Kochar N, Abraham P, Nair NG, Mehta AP. Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro. J Clin Microbiol. 1989 Oct;27(10):2328-30.

Biasco G, Paganelli GM, Brandi G, Brillanti S, Lami F, Callegari C, Gizzi G. Effect of Lactobacillus acidophilus and Bifidobacterium bifidum on rectal cell kinetics and fecal pH. Ital J Gastroenterol. 1991 Mar-Apr;23(3):142.

Bilard C, Biagini R, Dulbecco P, Iiritano E, Gambaro C , Mele M R , Borro P ,Tessieri L , Zentilin P , Mansi C, Vigneri S, Savarino V. Stool antigen assay (HpSA) is less reliable than urea breath test for post-treatment diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther. 2002 Oct;16(10):1733-8.

Brown AC, Valiere A. Probiotics and Medical Nutrition Therapy. Nutr Clin Care. 2004 Apr-Jun;7(2):56-68.

Burns AJ, Rowland IR. Anti-carcinogenicity of probiotics and prebiotics. Curr Issues Intest Microbiol. 2000 Mar;1(1):13-24.

Canducci F, Armuzzi A, Cremonini F, Cammarota G, Bartolozzi F, Pola P, Gasbarrini G, Gasbarrini A. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther. 2000 Dec;14(12):1625-9.

Cashman K. Prebiotics and calcium bioavailability. Curr Issues Intest Microbiol. 2003 Mar;4(1):21-32.

Cats A, Kuipers EJ, Boschaert MA, Pot RG, Vandenbroucke-Grauls CM, Custers JG. Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther. 2003 Feb;17(3):429-35.

Coconnier MH, Lievin V, Hemery E, Servin AL. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Environ Microbiol. 1998 Nov;64(11):4573-80.

Conway PL, Gorbach SL, Goldin BR. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J Dairy Sci. 1987 Jan;70(1):1-12.

Coudray C, Tressol JC, Gueux E, Rayssiguier Y. Effects of inulin-type fructans of different chain length and type of branching on intestinal absorption and balance of calcium and magnesium in rats. Eur J Nutr. 2003 Apr;42(2):91-8.

Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L, Nista EC, Cammarota G, Gasbarrini G, Gasbarrini A. Effect of different probiotic preparations on anti-Helicobacter pylori therapyrelated side effects: a parallel group, triple blind, placebocontrolled study. Am J Gastroenterol. 2002 Nov;97(11):2744-9.

Cruchet S, Obregon MC, Salazar G, Diaz E, Gotteland M. Effect of the ingestion of a dietary product containing Lactobacillus johnsonii La1 on Helicobacter pylori colonization in children. Nutrition. 2003 Sep;19(9):716-21.

Dicks LM, Botes M. Probiotic lactic acid bacteria in the gastro-intestinal tract: health benefits, safety and mode of action. Benef Microbes. 2010 Mar;1(1):11-29.

Donnet-Hughes A, Rochat F, Serrant P, Aeschlimann JM, Schiffrin EJ. Modulation of nonspecific mechanisms of defense by lactic acid bacteria: effective dose. J Dairy Sci. 1999 May;82(5):863-9.

Erickson KL, Hubbard NE. Probiotic immunomodulation in health and disease. J Nutr. 2000 Feb;130(2S Suppl):403S-409S.

Fang H, Elina T, Heikki A, Seppo SModulation of humoral immune response through probiotic intake. FEMS Immunol Med Microbiol. 2000 Sep;29(1):47-52.

Felley CP, Corthésy-Theulaz I, Rivero JL, Sipponen P, Kaufmann M, Bauerfeind P, Wiesel PH, Brassart D, Pfeifer A, Blum AL, Michetti P. Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol. 2001 Jan;13(1):25-9.

Francavilla R, Lionetti E, Castellaneta SP, Magistà AM, Maurogiovanni G, Bucci N, De Canio A, Indrio F, Cavallo L, Ierardi E, Miniello VL. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter. 2008 Apr;13(2):127-34.

Gebel J, Vacata V, Sigler K, Pietsch H, Rechenburg A, Exner M, Kistemann T. Disinfectant activity against different morphological forms of Helicobacter pylori: first results. J Hosp Infect. 2001 Aug;48 Suppl A:S58-63.

Gill HS, Guarner F. Probiotics and human health: a clinical perspective. Postgrad Med J. 2004 Sep;80(947):516-26.

Goldin BR, Gualtieri LJ, Moore RP. The effect of Lactobacillus GG on the initiation and promotion of DMH-induced intestinal tumors in the rat. Nutr Cancer. 1996;25(2):197-204.

Gordon M, Wardlaw Jeffrey S, Hampl Robert A, Disilvestro. Perspectives in Nutrition. 2006.6/e.

Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther. 2006 Apr;23(8):1077-86.

Gotteland M, Cruchet S. Suppressive effect of frequent ingestion of Lactobacillus johnsonii La1 on Helicobacter pylori colonization in asymptomatic volunteers. J Antimicrob Chemother. 2003 May;51(5):1317-9.

Gotteland M, Poliak L, Cruchet S, Brunser O. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus in children colonised by Helicobacter pylori. Acta Paediatr. 2005 Dec;94(12):1747-51.

Granato D, Perotti F, Masserey I, Rouvet M, Golliard M, Servin A, Brassart D. Cell surface-associated lipoteichoic acid acts as an adhesion factor for attachmentof Lactobacillus johnsonii La1 to huma enterocyte-like Caco-2 cells. Appl Environ Microbiol. 1999 Mar;65(3):1071-7.

Grill JP, Cayuela C, Antoine JM, Schneider F.Isolation and characterization of a Lactobacillus amylovorus mutant depleted in conjugated bile salt hydrolase activity: relation between activity and bile salt resistance. J Appl Microbiol. 2000 Oct;89(4):553-63.

Hata Y, Yamamoto M, Ohni M, Nakajima K, Nakamura Y, Takano T. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Am J Clin Nutr. 1996 Nov;64(5):767-71.

Hayatsu H, Hayatsu T. Suppressing effect of Lactobacillus casei administration on the urinary mutagenicity arising from ingestion of fried ground beef in the human. CancerLett.1993Sep;73(2-3):173-9.

Hirayama K, Rafter J. The role of probiotic bacteria in cancer prevention. Microbes Infect. 2000 May;2(6):681-6.

Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection.Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol. 1998 Dec;93(12):2330-8.

Jarosz M, Rychlik E, Siuba M, Respondek W, Ryżko-Skiba M, Sajór I, Gugała S, Błażejczyk T, Ciok J. Dietary and socio-economic factors in relation to Helicobacter pylori re-infection. World J Gastroenterol. 2009 Mar;15(9):1119-25.

Jin LZ, Ho YW, Abdullah N, Jalaludin S.Acid and bile tolerance of Lactobacillus isolated from chicken intestine. Lett Appl Microbiol. 1998 Sep;27(3):183-5.

Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, Okano M, Kagoshima M, Tsuchida T. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr. 2010 Jun;64(6):636-43.

Kalliomäki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotic and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003 May;361(9372):1869-71.

Kangatharalingam N, Amy PS. Helicobacter pylori comb. nov. Exhibits Facultative Acidophilism and Obligate Microaerophilism. Appl Environ Microbiol. 1994 Jun;60(6):2176-9.

Kawase M, Hashimoto H, Hosoda M, Morita H, Hosono A. Effect of Administration of Fermented Milk Containing Whey Protein Concentrate to Rats and Healthy Men on Serum Lipids and Blood Pressure. J Dairy Sci. 2000 Feb;83(2):255-63.

Kawase M, Hashimoto H, Hosoda M, Morita H, Hosono A. Effect of administration of fermented milk containing whey protein concentrate to rats and healthymen on serum lipids and blood pressure. J Dairy Sci. 2000 Feb;83(2):255-63.

Khedkar CD, Garge RD, Mantri JM, Kulkarni SA, Khedkar GD. Effect of feeding acidophilus milk on serum cholesterol in human volunteers of 50 – 60 years. J Dairy Foods Home Sci. 1993;12:33-38.

Kiebling G, Schneider J, Jahreis G. Long-term consumption of fermented dairy products over 6 months increases HDL cholesterol. Eur J Clin Nutr. 2002 Sep;56(9):843-9.

Klaver FA, van der Meer R. The assumed estimation of cholesterol removal by Lactobacilli and Bifidobacterium bifidum is due to their bile salt deconjugation activity. Appl Environ Microbiol. 1993 Apr;59(4):1120-4.

Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori Infection. Clin Microbiol Rev. 2006 Jul;19(3):449-90.

LeBlanc JG, Ledue-Clier F, Bensaada M, de Giori GS, Guerekobaya T, Sesma F, Juillard V, Rabot S, Piard JC. Ability of Lactobacillus
fermentum to overcome host alpha-galactosidase deficiency, as evidenced by reduction of hydrogen excretion in rats consuming soya alpha-galacto-oligosaccharides. BMC Microbiol. 2008 Jan;8:22.

Lee YK, Salminen S. The coming age of probiotics. Trends Food Sci Technol. 1995;6:241-245.

Lerebours E, N’Djitoyap Ndam C, Lavoine A, Hellot MF, Antoine JM, Colin R. Yogurt and fermented-then-pasteurized milk: effects of short-term and long-term ingestion on lactose absorption and mucosal lactase activity in lactase-deficient subjects. Am J Clin Nutr. 1989 May;49(5):823-7.

Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006 Dec;444(7122):1022-3.

Lidbeck A, Nord CE, Gustafsson JA, Rafter J. Lactobacilli,anticarcinogenic activities and human intestinal microflora. Eur J Cancer Prev. 1992 Aug;1(5):341-53.

Lin JT, Wang JT, Wang TH, Wu MS, Lee TK, Chen CJ. Helicobacter pylori infection in a randomly selected population, healthy volunteers, and patients with gastric ulcer and gastric adenocarcinoma. A seroprevalence study in Taiwan. Scand J Gastroenterol. 1993 Dec;28(12):1067-72.

Lin PW, Nasr TR, Berardinelli AJ, Kumar A, Neish AS. The probiotic Lactobacillus GG may augment intestinal host defense by regulating apoptosis and promoting cytoprotective responses in the developing murine gut. Pediatr Res. 2008 Nov;64(5):511-6.

Lin SY, Ayres JW, Winkler W Jr, Sandine WE. Lactobacillus Effects on Cholesterol: In Vitro and In Vivo Results. J Dairy Sci. 1989 Nov;72(11):2885-99.

Liu SN, Han Y, Zhou ZJ. Lactic acid bacteria in traditional fermented Chinese foods. Food Research International. 44 (2011) 643-651.

Lovegrove J, Jackson K. Coronary heart disease. In: Mattila Sandholm T, Saarela M, eds. Functional dairy products. Cambridge, UK: Woodhill Publishing, 2003 : 54-87.

Mann GV. Studies of a surfactant and cholesteremia in the Maasai. Am J Clin Nutr. 1974 May;27(5):464-9.

Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of
Patients with gastritis and pepticulceration. Lancet. 1984 Jun;1(8390):1311-5.

Midolo PD, Lambert JR, Hull R, Luo F, Grayson ML. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol. 1995 Oct;79(4):475-9.

Modler GW, McKellar RC, Yaguchi M. Bifidobacteria and bifidogenic factors. Can Inst Food Sci Technol J. 1990; 23:29-41.

Mrda Z, Zivanović M, Rasić J, Gajin S, Somer L, Trbojević S, Majoros J, Petrović Z. Therapy of Helicobacter pylori infection using Lactobacillus acidophilus. Med Pregl. 1998 Jul-Aug;51(7-8):343-5.

Myllyluoma E, Veijola L, Ahlroos T, Tynkkynen S, Kankuri E, Vapaatalo H, Rautelin H, Korpela R. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy – a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther. 2005 May;21(10):1263-72.

Nakamura Y, Masuda O, Takano T. Decrease of tissue angiotensin I-converting enzyme activity upon feeding sour milk in spontaneously hypertensive rats. Biosci Biotechnol Biochem. 1996 Mar;60(3):488-9.
Nijevitch AA. Helicobacter pylori-dependent intragastric urea biodegradation in children: diagnostic and pathogenic importance. Acta Paediatr Jpn. 1998 Apr;40(2):122-30.

Nobaek S, Johansson ML, Molin G, Ahrné S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 2000 May;95(5):1231-8.

Oh Y, Osato MS, Han X, Bennett G, Hong WK. Folk yoghurt kills Helicobacter pylori. J Appl Microbiol. 2002;93(6):1083-8.

Öztürk E. Diagnostic methods of Helicobacter pylori infection.Gülhane Týp Dergisi 2008; 50: 60-64.

Pantoflickova D, Corthésy-Theulaz I, Dorta G, Stolte M, Isler P, Rochat F, Enslen M, Blum AL. Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment Pharmacol Ther. 2003 Oct;18(8):805-13.

Perdigon G, Alvarez S, Pesce de Ruiz Holgado A. Immunoadjuvant activity of oral Lactobacillus casei: influence of dose on the secretory immune response and protective capacity in intestinal infections. J Dairy Res. 1991 Nov;58(4):485-96.

Rafter JJ. The role of lactic acid bacteria in colon cancer prevention. Scand J Gastroenterol. 1995 Jun;30(6):497-502.

Rolfe RD. The Role of Probiotic Cultures in the Control of Gastrointestinal Health. J Nutr. 2000 Feb;130(2S Suppl):396S-402S.

Sakamoto I, Igarashi M, Kimura K, Takagi A, Miwa T, Koga Y. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemother. 2001 May;47(5):709-10.

Schiffrin EJ, Rochat F, Link-Amster H, Aeschlimann JM and Donnet-Hughes A. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci. 1995 Mar;78(3):491-7.

Scholz-Ahrens KE, Acxil Y, Schrezenmeir J. Effect of oligofructose or dietary calcium on repeated calcium and phosphorus balances, bone mineralization and trabecular structure in ovariectomized rats. Br J Nutr. 2002;88:365-78.

Scholz-Ahrens KE, Ade P, Marten B, Weber P, Timm W, Ail Y, Glu C C, and Schrezenmeir J. Prebiotics, Probiotics, and Synbiotics Affect Mineral Absorption, Bone Mineral Content, and Bone Structure. J Nutr. 2007 Mar;137(3 Suppl 2):838S-46S.

Scholz-Ahrens KE, Schaafsma G, van den Heuvel EGHM, Schrezenmeir J. Effects of prebiotics on mineral metabolism. Am J Clin Nutr. 2001 Feb;73(2 Suppl):459S-64S.

Scholz-Ahrens KE, Schrezenmeir J. Inulin, oligofructose and mineral metabolism—experimental data and mechanism. Br J Nutr. 2002 May;87 Suppl 2:S179-86.

Sgouras D, Maragkoudakis P, Petraki K, Martinez-Gonzalez B, Eriotou E, Michopoulos S, Kalantzopoulos G, Tsakalidou E, Mentis A. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol. 2004 Jan;70(1):518-26.

Sheu BS, Wu JJ, Lo CY, Wu HW, Chen JH, Lin YS, Lin MD. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2002 Sep;16(9):1669-75.

Shimizu T, Haruna H, Hisada K, Yamashiro Y. Effects of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in children. J Antimicrob Chemother. 2002 Oct;50(4):617-8.

Sobala GM, Schorah CJ, Shires S, Lynch DAF, Gallacher B, Dixon MF, Axon ATR. Effect of eradication of Helicobacter pylori on gastric uice ascorbic acid concentrations. Gut. 1993 Aug;34(8):1038-41.

Suehara K, Yano T. Bioprocess monitoring using near-infrared spectroscopy. Adv Biochem Eng Biotechnol. 2004;90:173-98.

Sullivana A, Nord CE. Probiotics and gastrointestinal diseases. J Intern Med. 2005 Jan;257(1):78-92.

Takano T. Milk derived peptides and hypertension reduction. Int Dairy J 1998 ; 8:375-81.

Torres J, Pérez GP, Goodman KJ, Atherton JC, Gold BD, Harris PR, Garza A M de la,Guarner J and Muñoz O. A Comprehensive Review of the Natural History of Helicobacter pylori Infection in Children. Arch Med Res. 2000 Sep-Oct;31(5):431-69.

Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006 Dec;444(7122):1027-31.

Vandenplas Y.Helicobacter pylori infection. World J Gastroenterol. 2000 Feb;6(1):20-31.

Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis. 2008 Nov;14(11):1585-96.

Wang KY, Li SN, Liu CS, Perng DS, Su YC, Wu DC, Jan CM, Lai CH, Wang TN, and Wang WM. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nutr. 2004 Sep;80(3):737-41.

Wendakoon CN, Thomson ABR, Ozimek L. Lack of therapeutic effect of a specially designed yogurt for the eradication of Helicobacter pylori. Digestion. 2002;65(1):16-20.

Yan F, Polk DB. Commensal bacteria in the gut: learning who our friends are. Curr Opin Gastroenterol. 2004 Nov;20(6):565-71.

Yan F, Polk DB. Probiotics: progress toward novel therapies for intestinal diseases. Curr Opin Gastroenterol. 2010 Mar;26(2):95-101.

Yáñez P, Madrazo-de la GA, Pérez-Pérez GI, Cabrera L, Muñoz O, Torres J. Comparison of invasive and non-invasive methods forthe diagnosis and evaluation of eradication of Helicobacter pylori infection in children. Arch Med Res. 2000 Jul-Aug;31(4):415-21

Ying D, Sanguansri L, Weerakkody R, Singh TK, Leischtfeld SF, Gantenbein-Demarchi C, Augustin MA.Tocopherol and ascorbate have contrasting effects on the viability of microencapsulated Lactobacillus rhamnosus GG. J Agric Food Chem. 2011 Oct ;59(19):10556-63. Epub 2011 Sep 16.

Yoshio Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol. 2010 Nov;7(11):629-41.

連結至畢業學校之論文網頁點我開啟連結
註: 此連結為研究生畢業學校所提供,不一定有電子全文可供下載,若連結有誤,請點選上方之〝勘誤回報〞功能,我們會盡快修正,謝謝!
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top